Standard Biotools Inc (LAB)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $279.27M
Last updated: Nov 17, 2026 at 11:02 AM ET
Standard Biotools Inc (LAB) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, Standard Biotools reported EPS of -$0.06, below the -$0.01 estimate. It beat the EPS estimate in 1 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
LAB's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
LAB Earnings Call
The latest LAB earnings call transcript on file is labeled 2025Q1.
Read the 2025Q1 transcriptEarnings History
Of the 39 quarters below that had an estimate, LAB beat 15, missed 20 and matched 4. Revenue for the quarter ended Sep 30, 2026 was $19.39M, down 0.8% from $19.55M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.06 | -$0.01 | N/A | -500.00% | Miss | N/A | 1 | 0 up, 0 down | Nov 3, 2026 | $19.39M |
| Jun 30, 2026 | -$0.05 | -$0.03 | -$0.03 - -$0.03 | -66.67% | Miss | N/A | 1 | 1 up, 0 down | Aug 5, 2026 | $20.10M |
| Mar 31, 2026 | -$0.02 | -$0.02 | -$0.02 - -$0.02 | 0.00% | In line | N/A | 2 | 0 up, 1 down | May 5, 2026 | $21.15M |
| Dec 31, 2025 | $0.07 | -$0.05 | N/A | +226.08% | Beat | N/A | 2 | 1 up, 0 down | Feb 24, 2026 | $3.22M |
| Sep 30, 2025 | -$0.04 | -$0.02 | -$0.02 - -$0.02 | -100.00% | Miss | N/A | 1 | 1 up, 0 down | Nov 4, 2025 | $19.55M |
| Jun 30, 2025 | -$0.04 | -$0.04 | -$0.04 - -$0.04 | 0.00% | In line | N/A | 2 | 0 up, 0 down | Aug 11, 2025 | $21.76M |
| Mar 31, 2025 | -$0.05 | -$0.04 | -$0.04 - -$0.04 | -25.00% | Miss | N/A | 2 | 0 up, 0 down | May 6, 2025 | $20.22M |
| Dec 31, 2024 | -$0.05 | -$0.03 | -$0.03 - -$0.03 | -64.67% | Miss | N/A | 2 | 0 up, 0 down | Feb 26, 2025 | $890000 |
| Sep 30, 2024 | -$0.03 | -$0.07 | N/A | +57.14% | Beat | N/A | 3 | 0 up, 0 down | Oct 30, 2024 | $22.09M |
| Jun 30, 2024 | -$0.08 | -$0.07 | N/A | -14.29% | Miss | N/A | 2 | 0 up, 0 down | Jul 31, 2024 | $22.49M |
| Mar 31, 2024 | -$0.24 | -$0.10 | N/A | -140.00% | Miss | N/A | N/A | 0 up, 0 down | May 8, 2024 | $45.54M |
| Dec 31, 2023 | -$0.25 | -$0.13 | N/A | -92.31% | Miss | N/A | 1 | 0 up, 0 down | Feb 28, 2024 | $28.19M |
| Sep 30, 2023 | -$0.14 | -$0.12 | N/A | -16.67% | Miss | N/A | N/A | 0 up, 0 down | Nov 7, 2023 | $25.37M |
| Jun 30, 2023 | -$0.14 | -$0.10 | N/A | -40.00% | Miss | N/A | N/A | 0 up, 0 down | Aug 8, 2023 | $27.67M |
| Mar 31, 2023 | -$0.21 | -$0.06 | N/A | -250.00% | Miss | N/A | N/A | 0 up, 0 down | May 9, 2023 | $25.12M |
| Dec 31, 2022 | -$0.26 | -$0.28 | N/A | +7.14% | Beat | N/A | N/A | 0 up, 0 down | Feb 14, 2023 | $27.02M |
| Sep 30, 2022 | -$0.37 | -$0.13 | N/A | -184.62% | Miss | N/A | N/A | 0 up, 0 down | Nov 8, 2022 | $25.65M |
| Jun 30, 2022 | -$0.33 | -$0.15 | N/A | -120.00% | Miss | N/A | N/A | 0 up, 0 down | Aug 8, 2022 | $18.78M |
| Mar 31, 2022 | -$0.25 | -$0.18 | N/A | -38.89% | Miss | N/A | N/A | 0 up, 0 down | May 5, 2022 | $26.50M |
| Dec 31, 2021 | -$0.12 | -$0.28 | N/A | +57.14% | Beat | N/A | N/A | N/A | Feb 17, 2022 | $38.27M |
| Sep 30, 2021 | -$0.07 | -$0.11 | N/A | +36.36% | Beat | -333.3% | N/A | N/A | Nov 8, 2021 | $28.50M |
| Jun 30, 2021 | -$0.12 | -$0.08 | N/A | -50.00% | Miss | N/A | N/A | N/A | Aug 5, 2021 | $31.02M |
| Mar 31, 2021 | -$0.15 | -$0.04 | N/A | -275.00% | Miss | N/A | N/A | N/A | May 6, 2021 | $32.79M |
| Dec 31, 2020 | -$0.13 | $0.01 | N/A | N/A | N/A | N/A | N/A | N/A | Feb 10, 2021 | $44.61M |
| Sep 30, 2020 | $0.03 | -$0.11 | N/A | +127.27% | Beat | N/A | N/A | N/A | Nov 5, 2020 | $39.86M |
| Jun 30, 2020 | -$0.07 | -$0.14 | N/A | +50.00% | Beat | N/A | N/A | N/A | Aug 6, 2020 | $26.06M |
| Mar 31, 2020 | -$0.13 | -$0.10 | N/A | -30.00% | Miss | N/A | N/A | N/A | May 7, 2020 | $27.62M |
| Dec 31, 2019 | -$0.03 | -$0.09 | N/A | +66.67% | Beat | N/A | N/A | N/A | Feb 10, 2020 | $32.44M |
| Sep 30, 2019 | -$0.09 | -$0.09 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 5, 2019 | $26.50M |
| Jun 30, 2019 | -$0.10 | -$0.07 | N/A | -42.86% | Miss | N/A | N/A | N/A | Aug 1, 2019 | $28.20M |
| Mar 31, 2019 | -$0.14 | -$0.10 | N/A | -40.00% | Miss | N/A | N/A | N/A | May 2, 2019 | $30.11M |
| Dec 31, 2018 | -$0.06 | -$0.19 | N/A | +68.42% | Beat | N/A | N/A | N/A | Feb 7, 2019 | N/A |
| Sep 30, 2018 | -$0.13 | -$0.18 | N/A | +27.78% | Beat | N/A | N/A | N/A | Nov 1, 2018 | $53.20M |
| Jun 30, 2018 | -$0.23 | -$0.23 | N/A | 0.00% | In line | N/A | N/A | N/A | Aug 2, 2018 | $48.20M |
| Mar 31, 2018 | -$0.21 | -$0.30 | N/A | +30.00% | Beat | N/A | N/A | N/A | May 3, 2018 | $66.20M |
| Dec 31, 2017 | -$0.15 | -$0.25 | N/A | +40.00% | Beat | N/A | N/A | N/A | Feb 8, 2018 | $27.75M |
| Sep 30, 2017 | -$0.25 | -$0.31 | N/A | +19.35% | Beat | N/A | N/A | N/A | Nov 2, 2017 | $24.75M |
| Jun 30, 2017 | -$0.31 | -$0.34 | N/A | +8.82% | Beat | N/A | N/A | N/A | Aug 3, 2017 | $23.91M |
| Mar 31, 2017 | -$0.33 | -$0.56 | N/A | +41.07% | Beat | N/A | N/A | N/A | May 4, 2017 | $25.53M |
| Dec 31, 2016 | -$0.32 | -$0.23 | N/A | -39.13% | Miss | N/A | N/A | N/A | Feb 8, 2017 | $114.09M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.06, after -$0.40 the year before. It was -$1.44 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.06 | N/A |
| Dec 31, 2024 | -$0.40 | N/A |
| Dec 31, 2023 | -$0.74 | N/A |
| Dec 31, 2022 | -$1.21 | N/A |
| Dec 31, 2021 | -$0.46 | N/A |
| Dec 31, 2020 | -$0.30 | N/A |
| Dec 31, 2019 | -$0.36 | N/A |
| Dec 31, 2018 | -$0.63 | N/A |
| Dec 31, 2017 | -$1.04 | N/A |
| Dec 31, 2016 | -$1.44 | N/A |
Earnings Calls
The 4 most recent earnings calls are listed below; the latest, 2025Q1 for the period ended Mar 31, 2025, runs about 4,900 words across 7 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2025Q1 | Mar 31, 2025 | 4,891 | 7 | |
| 2024Q4 | Dec 31, 2024 | 5,478 | 7 | |
| 2024Q3 | Sep 30, 2024 | 4,496 | 6 | |
| 2024Q2 | Jun 30, 2024 | 5,313 | 7 |
2025Q1 Earnings Call
Opening remarks
John Graziano VP of IR Good day and welcome to the Standard BioTools, Inc., First Quarter 2025 Financial Results Conference Call. Please note this event is being recorded. I would now like to turn the conference over to John Graziano, Vice President of Investor Relations. Please go ahead.
Michael Egholm President & CEO Thank you, John. Good afternoon, everyone, and welcome to Standard BioTools' first quarter 2025 earnings call. Joining me today is Alex Kim, our Chief Financial Officer. Before we begin, I want to thank our customers, employees, and investors. Your support is what fuels our work and drives our mission to set a new standard in life sciences, empower researchers, accelerate in discovery, all while delivering long-term value to our shareholders. Standard BioTools delivered a solid first quarter with results on plan and in line despite a choppy operating backdrop. Execution continues to improve as we build rigor across the organization, guided by lean principles through our Standard BioTools Business System or just SBS. As operators, we're staying grounded in fundamentals, focusing on what we can control, managing with precision, and driving toward profitability. Before diving into the details, it's worth stepping back for a moment. While the broader environment remains dynamic, we're navigating it from a position of strength with a diversified portfolio, a disciplined operating model, healthy balance sheet, and a team that's getting sharper quarter after quarter as forecast accuracy improves and consistency in how we run the business grows. We are particularly pleased with our strategic foothold in proteomics and a series of recent high-impact product launches. Last week at the American Association of Cancer Research's annual meeting, or AACR, we announced a new SomaScan offering that will pair well with the highly anticipated distributed NGS-based Illumina partner solution. Together, these advancements expand our reach and push the boundaries of what's possible in translational and clinical research. From the outside, the macro backdrop may still cloud the picture, but inside we're strong. Our diversified business and life sciences allows us to operate multiple levels to navigate the waters, including a patient and disciplined M&A strategy, which is benefiting from a growing number of compelling assets and opportunities. With that, let's turn to the numbers. In Q1, while not growth, we executed to plan and delivered $40.8 million in revenue. This was down 10% year-over-year as the market got worse against last year's Q1, and we had elevated backlog to start 2024. Despite this and not enough to wave the all-clear flag, we have seen encouraging traction in capital expenditures, which strengthened our instrument business, which is also helped by a favorable year-over-year comp.
Frequently Asked Questions About LAB
Did LAB beat earnings estimates last quarter?
No. Standard Biotools reported EPS of -$0.06 for the quarter ended Sep 30, 2026, below the -$0.01 estimate by 500.00%.
What EPS do analysts expect from LAB next quarter?
The consensus EPS estimate for Standard Biotools for the quarter ending Dec 31, 2026 is -$0.02 from 2 analysts, with estimates from -$0.02 to -$0.02.
How often does LAB beat earnings estimates?
Standard Biotools beat the EPS estimate in 1 of the last 8 quarters, with an average surprise of -66.28%.
LAB pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts